Latest News
Symbiomix Therapeutics Receives FDA Approval for Solosec (secnidazole) Oral Granules for Treatment of Bacterial Vaginosis in Adult Women
19 September 2017 - - US-based biopharmaceutical company Symbiomix Therapeutics has received US Food and Drug Administration (FDA) approval for Solosec (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women, the c...
FDA Approves Optinose's Xhance Nasal Spray for the Treatment of Nasal Polyps
19 September 2017 - - Yardley, Pennsylvania-based otolaryngology and allergy therapeutics developer Optinose has received approval from the US Food and Drug Administration (FDA) of its New Drug Application (NDA) for Xhance (previously referred to by ...
Mitobridge Licenses Intellectual Property Related to NAD+ Modulation as a Therapeutic Approach for Improving Mitochondrial Function
19 September 2017 - - Cambridge, Massachusetts-based mitochondrial function-focused Mitobridge, Inc. has broadened its therapeutic approach to include nicotinamide adenine dinucleotide (NAD+) pathway modulation, the company said.
Mitobridge ha...
Genentech Reports Positive Results of Venclexta Plus Rituxan in Patients with Previously Treated CLL Compared to Bendamustine Plus Rituxan
19 September 2017 - - South San Francisco, California-based biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), has provided positive results from the Phase III MURANO study, which evaluated Venclexta (vene...
Formula Pharmaceuticals Initiates First Clinical Trial of Allogeneic CIK-CAR Cancer Immunotherapy
19 September 2017 - - Berwyn, Pennsylvania-based immuno-oncology-focused Formula Pharmaceuticals, Inc. has opened the first clinical trial for allogeneic Cytokine Induced Killer (C.I.K.) cell-based Chimeric Antigen Receptor (CAR) cancer immunotherapy...